ClinicalTrials.gg
TerminatedNCT06386874Updated Nov 19, 2026

EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment

An interventional study of Q Therapeutic System (BQ 3.0) - Sham and Q Therapeutic System (BQ 3.0) - Active in Ischemic Stroke, sponsored by BrainQ Technologies Ltd.. Terminated at 14 sites in United States. Open to participants aged 22 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by BrainQ Technologies Ltd. · Not applicable, Interventional, and Supportive care

How we know

Why this study was terminated
Poor accrual
Updated Nov 19, 2026Now TerminatedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
22 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 480 studies in Ischemic Stroke with a site in United States — 120 open to participants now, 145 under way, 13 of them phase 3. Ischemic Stroke · United States.

Enrollment
187th of 364
62 · median 65
Started
2024
with 30 others
No phase
183 of 480
51 open now
Registered
411th of 480
by date

Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 187th largest by enrollment of the 364 interventional ones that give a count, is one of 31 that started in 2024, is one of 183 with no phase, and was the 411th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

120 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 22 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter study that will be conducted at approximately 20 centers and up to 30 centers, if the sample size will be increased following interim assessment.

The Q Therapeutic System (BQ 3.0) is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery.

The Q Therapeutic System (BQ 3.0) is indicated for adjunctive use in a clinical facility or home setting, in addition to standard-of-care therapies.

  • In Stage 1 (starting 4-21 days after the index stroke event to day 90 post stroke), participants will be randomly assigned (1:1) to receive either active or the sham treatments, up to 5 times a week, and at least to a total of 45 treatments.
  • In Stage 2 (day 90 to day 180 post stroke), participants in both the active and the control group will be allowed to continue to receive active treatments, up to 5 times per week.
  • In stage 3 (day 180 to day 270 post stroke), participants will not receive any treatments and would be followed up until the final visit at day 270.

Each session will last approximately 60 minutes, with stimulation activated for up to 40 minutes, in conjunction with a home-based exercise program. Treatments may be administered in the hospital, in the clinic or in a home setting.

The study will enroll 100-122 adult subjects who will be randomly assigned (1:1 allocation ratio) to either active or sham study intervention using the BQ 3.0 system.

Read the detailed description

The study intervention will be initiated 4-21 days after the index stroke event and will consist of 5 treatments per week until the primary endpoint follow-up visit, at day 90 (±15) after the onset of the index stroke. A minimum of 45 treatment sessions should be completed during this stage, with a potential of a maximum of 72 treatment sessions, depending on the start date of the first treatment and the timing of the 90-day follow-up visit. Though, participants and sites will be guided to conduct the 90 days follow-up visit as soon as possible after the 45th treatment session and within up to 7 days from the 45th treatment and after the window opening.

Each treatment session will last approximately 60 minutes and include 40 minutes of active or sham stimulation. Subjects in both groups will be asked to perform a home-based exercise program for the upper and the lower limb, concurrent with the study intervention.

Screening phase:

Prospective subjects, who are 3 to 21 days post-stroke, may be offered informed consent to participate in the study at either:

a participating inpatient or outpatient center, non-participating inpatient or outpatient center, in accordance with both the participating and the non-participating centers' policy, or home Consented subjects, who are 4 to 21 days post-stroke, will be screened for eligibility to participate in the treatment phase of the study.

Eligible subjects will be randomly assigned, at a 1:1 allocation ratio, to either the active or sham study intervention groups.

Stimulation with the Q Therapeutic System (BQ 3.0) does not produce any noticeable sound, light, or tactile sensation which could disclose the treatment arm assignment, making this device ideal for testing in a sham-controlled design. During sham treatment sessions, for purposes of maintaining the blind, the device will function as if it is delivering the therapy (i.e., the device will turn on and all indicators will function), but the frequency and intensity parameters, which are not visible to the subject or site study members (or any blinded personnel), will be set to zero so that no stimulation is delivered.

Stage 1 (day 4 to day 90 (±15) post-stroke) - double-blind sham-controlled:

Efforts should be made to initiate the 1st treatment as early as possible within the window of recruitment, and target to complete a first treatment within 6 days from admission to a participating IRF (where applicable). The study intervention will be initiated 4-21 days after the index stroke event and will consist of 5 treatments per week until the primary endpoint follow-up visit, at day 90 (±15) after the onset of the index stroke. Each treatment session will last approximately 60 minutes and include 40 minutes of active or sham stimulation. Subjects in both groups will be asked to perform a home- based exercise program for the upper and the lower limb, concurrent with the study intervention. The program will be standardized, pre-defined, home-based, and aligned with standard-of-care1.

The participant and their caregiver will be trained on the use of the device and exercise program. Treatment sessions will be completed by the subject with the assistance of a trained caregiver, as needed. Periodic supervision will be provided by the study team (combined audio and video remote conferencing or audio only, if video is not available). A sponsor's representative may provide in-person or remote technical support to the participant and their caregiver, as well as device training, as needed.

Subjects will undergo a detailed interim outcome assessment on the 45th (±4) day after the onset of the index stroke, and a detailed primary endpoint outcome assessment on the 90th (±15) day after the onset of the index stroke. In addition, a focused, long-term outcome assessment on the 180th (±15) day after the onset of the index stroke will be performed.

Stage 2 (day 90 (±15) to day 180 (±15) post-stroke) - open-label:

Subjects in both the active and the sham groups (active /sham), who were adherent to the treatment in Stage 1 (defined as at least 35 completed treatment sessions in Stage 1) will be allowed to continue to receive active EMFstimulation treatments (i.e., with the electromagnetic therapy turned on).

Up to 5 active treatments per week will be completed, starting following the primary endpoint assessment follow-up visit at 90 (±15) days after the onset of the index stroke and continuing until the follow-up visit at 180 (±15) days after the onset of the index. Technically, a maximum of 86 treatment sessions can be completed during stage 2, depending on the timing of the 90-day and 180-day follow-up visits.

The blind, with respect to the group allocation in Stage 1, would be maintained for all parties (participants, investigators, assessors and Sponsor) until the trial completion and database lock.

Each session will last approximately 60 minutes and include 40 minutes of active stimulation. Subjects will be asked to perform a home-based exercise program, concurrent with the study intervention.

Treatment sessions will be completed by the subject with the assistance of a trained caregiver, as needed. Periodic supervision will be provided by the study team (combined audio and video remote conferencing or audio only, if video is not available). A sponsor's representative willmay provide in-person or remote technical support to the participant and their caregiver, as well as device training, as needed.

All subjects, including those who decided not to continue to receive treatments in Stage 2, will undergo a detailed follow-up assessment on the 180th (±15) day after the onset of the index stroke.

Stage 3 (day 180 (±15) to day 270 (±15) post-stroke):

At this Stage, no treatments sessions will take place. All subjects, including those who decided not to continue to receive treatments in Stage 2, will undergo In addition, aa focused, long-term outcome assessment on the 180th 270th (±15) day after the onset of the index stroke will be performed.

Any adverse events and device deficiencies occurring during the period of subject's participation in the trial will be recorded.

Participation in the study will not replace any of the usual care patient should receive.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
22 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. mRS score of 3 or 4.
  2. FMA-UE score between 10-45 (inclusive) of impaired limb.
  3. SAFE score >0.
  4. Age 22 to 80 years of age (inclusive).
  5. Diagnosed with an ischemic stroke, confirmed by CT4 or MRI5 imaging.
  6. First ever ischemic stroke, or a recurring ischemic stroke6 occurring at least 3 months after the previous stroke (any stroke), without residual neurological impairment or disability before current stroke.
  7. Four to 21 days from stroke onset (or last known well).
  8. Pre-stroke mRS of 0.
  9. Able to sit with the device for 40 consecutive minutes, in the opinion of the investigator or designee.
  10. Can follow a 3-step command, such as "take the paper, fold it in half, and return it to me".
  11. Willingness to participate in an exercise activity during study intervention sessions.
  12. Availability of a relative or other caregiver able to assist in operating an application installed on a mobile device, including a video call, and assist the participant with the exercising program.
  13. If female, not pregnant (as confirmed by a urine or a blood test, or as determined by an official medical document) or breastfeeding and with no ability to become pregnant or on an acceptable method of during the study
  14. signed by subject.

Exclusion criteria

Exclusion Criteria:

  1. Hemineglect impairment (NIHSS item 11, score >0).
  2. Implanted active electronic or passive MR-incompatible devices.
  3. Pre-existing major neurological condition (eg, Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, spinal cord injury) or pre-existing physical limitation that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
  4. Active epilepsy or currently taking anti-epileptic medication (indicated for the treatment of a seizure disorder), or any epileptic seizure in the last 5 years
  5. Significant visual disturbances, pre-existing or resulting from the index stroke, that cannot be corrected and that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
  6. Unstable serious illness/condition (eg, active cancer, severe heart failure, active major psychiatric condition) or of less than 12 months.
  7. A known severe allergic reaction to acrylic-based adhesives.
  8. Alcohol abuse and/or illicit drug abuse in the past 6 months, which is likely to influence ability to fully participate in the trial.
  9. Participation in another trial that would conflict with the current study or clinical endpoint interference may occur.
  10. Employee of the Sponsor.
  11. Prisoner.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Sham comparator
    BQ 3.0 Sham Stimulation Group

    Q Therapeutic System (BQ 3.0) sham stimulation group: Device used: Q Therapeutic System (BQ 3.0) In Stage 1: 45 sessions over a period of 9 weeks (5 treatments per week) of sham study intervention with BQ 3.0 (frequency and intensity parameters will be set to zero so that no stimulation is delivered) including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.

    Device: Q Therapeutic System (BQ 3.0) - Sham · Device: Q Therapeutic System (BQ 3.0) - Active

  • Active comparator
    BQ 3.0 Active Stimulation Group

    Q Therapeutic System (BQ 3.0) active stimulation group: Device used: Q Therapeutic System (BQ 3.0) In Stage 1: 45 sessions over a period of 9 weeks (5 treatments per week) of active study intervention with the BQ 3.0 (frequency and intensity parameters will be set to 1-100 Hz.; 0.1-1.0 G), including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.

    Device: Q Therapeutic System (BQ 3.0) - Sham · Device: Q Therapeutic System (BQ 3.0) - Active

Interventions

  • DeviceQ Therapeutic System (BQ 3.0) - Sham

    The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. Frequency and intensity parameters will be set to zero so that no stimulation is delivered.

    Also known as: BQ 3.0 Sham Stimulation Group

  • DeviceQ Therapeutic System (BQ 3.0) - Active

    The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery

    Also known as: BQ 3.0 Active Stimulation Group Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Modified Rankin Scale

    Proportion of subjects achieving an excellent outcome defined as a Modified Rankin Scale (mRS) score of 0-1 at the 90-day post-stroke assessment, reflecting freedom from disability.

    Time frame: 4 to 21 days following an ischemic stroke to 90-day post-stroke

Secondary outcomes

  1. Ordinal shift analysis of the mRS (trichotomized at 0-1, 2, 3-6) (Key Secondary Effectiveness Endpoint)

    Time frame: baseline to the 90-day post-stroke assessment

  2. Change from Baseline in Modified Rankin Scale (Key Secondary Effectiveness Endpoint)

    To show that the BQ therapy is effective in reducing disability levels

    Time frame: baseline (4-21 days post-stroke) to 90 days post-stroke

  3. Proportion of subjects achieving functional independence (mRS score of 0-2) (Key Secondary Effectiveness Endpoint)

    To show that the BQ therapy is effective in achieving functional independence.

    Time frame: at the 90-day post-stroke assessment

  4. Stroke Impact Scale Hand Domain (Lead Secondary Endpoint)

    Patient reported hand function - To show that the BQ therapy is effective in improving upper limb impairment and function

    Time frame: baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke

  5. Stroke Impact Scale 16

    Patient-reported physical function - To show that the BQ therapy is effective in improving physical function

    Time frame: baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke

  6. 10-meter Walk Test

    The Functional Ambulation Categories (FAC) will be collected concurrent to the 10MWT to assess the level of independent ambulation.

    Time frame: change from baseline to 90 days post-stroke

  7. Box and Block Test

    Arm motor function - To show that the BQ therapy is effective in improving Arm motor function

    Time frame: baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke

  8. Evaluation of 5-level EQ-5D

    Health-related quality of life - To show that the BQ therapy is effective in achieving health-related quality of life (HRQoL)

    Time frame: At 90-days post-stroke

  9. Fugl-Meyer Assessment for Upper Extremity (FMA-UE)

    upper limb impairment - To show that the BQ therapy is effective in achieving reducing upper limb impairment, and improving upper limb function

    Time frame: baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke

  10. Nine-Hole Peg Test

    finger dexterity - To show that the BQ therapy is effective in achieving reducing upper limb impairment, and improving upper limb function

    Time frame: change from baseline to 90-days post-stroke

  11. The proportion of subjects within those in the active group who continued to receive treatments in Stage 2, achieving an excellent outcome (defined as a mRS of 0-1) at the 180-day post-stroke assessment.

    To show, within those in the active group who continued to receive treatments in Stage 2, that the BQ therapy is effective in attaining freedom from disability, as well as reducing global disability, at 6 months post-stroke in disabled patients when initiated 4 to 21 days following an ischemic stroke.

    Time frame: at the 180-day post-stroke assessment

  12. The proportion of patients within those in the active group who continued to receive treatments in Stage 2, who achieved an excellent outcome defined as a mRS score of 0-1 at the 90-day post-stroke assessment and had an mRS >1 at 180-day post-stroke

    To show, within those in the active group who continued to receive treatments in Stage 2, that the BQ therapy is effective in attaining freedom from disability, as well as reducing global disability, at 6 months post-stroke in disabled patients when initiated 4 to 21 days following an ischemic stroke

    Time frame: at 180 days post-stroke

  13. The proportion of patients within those in the active group who continued to receive treatments in Stage 2, who achieved an excellent outcome defined as mRS score of 0-1 at the 180-day post-stroke assessment and had an mRS >1 at 270 days post-stroke.

    To show, within those in the active group who continued to receive treatments in Stage 2, that the effect attained in obtaining freedom from disability, as well as reducing global disability, is maintained at 6- and 9- months post-stroke in disabled patients with upper limb motor impairment when initiated 4 to 21 days following an ischemic stroke.

    Time frame: at 270 days post-stroke

  14. Ordinal shift analysis of the mRS (4 levels at 0, 1, 2, 3-6) from the 90-day post-stroke assessment to 180-day post-stroke assessment, within those in the active group who continued to receive treatments in Stage 2

    Time frame: from the 90-day post-stroke assessment to 180-day post-stroke assessment

  15. The proportion of patients who improved by at least 1 level on the mRS from the 90-day post-stroke assessment to 180-day post-stroke assessment, within those in the active group who continued to receive treatments in Stage 2.

    To show, within those in the active group who continued to receive treatments in Stage 2, that the BQ therapy is effective in attaining freedom from disability, as well as reducing global disability, at 6 months post-stroke in disabled patients when initiated 4 to 21 days following an ischemic stroke

    Time frame: from the 90-day post-stroke assessment to 180-day post-stroke assessment

  16. The proportion of subjects within those in the sham group who continued to receive treatments in Stage 2, achieving an excellent outcome (defined as a mRS of 0-1) at the 180-day post-stroke assessment, and had an mRS >1 at 90 days post-stroke.

    To show, within those in the sham group who continued to receive treatments in Stage 2 that the BQ therapy is effective in attaining freedom from disability, as well as reducing global disability, at 6 months post-stroke in disabled patients when initiated 90 days following an ischemic stroke

    Time frame: from the 90-day assessment to the 180-day assessment

Other outcomes

  1. Serious procedure or device related adverse events & device deficiencies

    To characterize the safety profile of the BQ therapy and to show that the BQ 3.0 performs reliably.

    Time frame: Through study completion, an average of 90 ± 15 days post-stroke

  2. Change in Montreal Cognitive Assessment (global cognitive function)

    To show that the BQ therapy is effective in reducing cognitive impairment, at 3 months post-stroke, when initiated 4 to 21 days following an ischemic stroke.

    Time frame: at 90-day post-stroke

  3. Change in Patient Health Questionnaire-8 (depression)

    To show that the BQ therapy is effective in reducing depression, at 3 months post-stroke, when initiated 4 to 21 days following an ischemic stroke.

    Time frame: at 90-day post stroke

  4. Academic Medical Center Linear Disability Scale (granular level of disability)

    To show that the BQ therapy is effective in reducing fine-grained level of disability at 3 months post-stroke

    Time frame: At 90 days post stroke

  5. Proportion of subjects achieving functional independence (modified Rankin Scale score of 0-1)

    To show that the BQ therapy is effective in increasing functional independence at 1.5 months post-stroke

    Time frame: at 45 days post-stroke

  6. Zarit Burden Interview

    To formally evaluate the cost-effectiveness of the BQ therapy via caregiver burden.

    Time frame: at midterm, 90 days post-stroke, 180 days post-stroke, and 270 days post-stroke.

  7. Formal cost-effectiveness analysis over a lifetime horizon from the perspective of the United States healthcare system.

    To formally evaluate the cost-effectiveness of the BQ therapy over a lifetime horizon from the perspective of the United States healthcare system

    Time frame: will be assessed at MidTerm (45 Day ± 4 days post- stroke) , Day-90 and D-180 post stroke

  8. Relationship between adherence to treatment as measured by the Qompass and the clinical outcomes.

    To explore the relationship between adherence to treatment as measured by the Qompass and clinical outcomes.

    Time frame: Will be assessed upon data base lock

  9. The proportion of patients within those in the sham group who continued to receive treatments in Stage 2 who improved from the 90-day assessment to 180-day and the improvement was maintained at 270 days post-stroke

    To show, within those in the sham group who continued to receive treatments in Stage 2 that the BQ therapy is effective in improving functional independence at 6 months post-stroke, when initiated 90 days following an ischemic stroke.

    Time frame: At 180 days post stroke and 270 days post-stroke

07

Study locations

14 sites
08

References and documents

Individual participant data

Plan to share: No — will be shared following site level approval

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2024 to primary completion in Dec 2025, 16 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Jul 2026 → Dec 2025 and completion Oct 2026 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2024
First posted
Apr 26, 2024
StartActual
Aug 20, 2024
Primary completionActual
Dec 26, 2025was Jul 2026
CompletionActual
Apr 7, 2026was Oct 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Poor accrual
changed Nov 19, 2026
Sites
1 site added, 1 site removed
Show site
  • MedStar National Rehabililtaion Hospital, · Washington D.C., United States
Show 1 removed
  • MedStar National Rehabililtaion Hospital, · Washington, United States
Nov 19, 2026
Primary completion
Jul 2026→Dec 26, 2025 (actual)
Nov 19, 2026
Study completion
Oct 2026→Apr 7, 2026 (actual)
Nov 19, 2026
Enrollment
122 (estimated)→62 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Recruiting→Terminated
    Why stopped Poor accrual
    1 site added, 1 site removed
    Show site
    • MedStar National Rehabililtaion Hospital, · Washington D.C., United States
    Show 1 removed
    • MedStar National Rehabililtaion Hospital, · Washington, United States
    Primary completion Jul 2026→Dec 26, 2025 (now actual)
    Study completion Oct 2026→Apr 7, 2026 (now actual)
    Enrollment 122 (estimated)→62 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06386874
Lead sponsor
BrainQ Technologies Ltd.
Responsible party
Sponsor
First posted
Apr 26, 2024
Start date
Aug 20, 2024
Primary completion
Dec 26, 2025
Completion
Apr 7, 2026
Last update
Nov 19, 2026

Study contacts

Jeffrey L. Saver, MD
study chair · Coordinating PI
Joel Stein, MD
principal investigator · Coordinating PI

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion